We are monitoring the impact of COVID-19 on Europe Liquid Biopsy Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 891
Share on
Share on

Europe Liquid Biopsy Market Research Report – Segmented By Cancer Type, Sample Type, Diagnostic Approach, End Users, Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2021 to 2026)

Pulished: April, 2021
ID: 891
Pages: 145

Europe Liquid Biopsy Market Size (2021 to 2026)

The European Liquid Biopsy Market size is estimated to value USD 1497.66 million by 2026 from USD 566.80 million in 2021, growing at a CAGR of 21.45% during the forecast period.

Europe Liquid Biopsy market led the global liquid biopsy market in 2019. In the coming years, the global liquid biopsy market is expected to undergo significant changes. Currently, the global market is just beginning, but it is still growing at a significant rate. Many start-ups and promising companies are entering the market.

Currently, in Europe Liquid Biopsy Market, research and development on cancer diagnosis focus on liquid biopsy. Market participants and research institutes are conducting extensive clinical trials to develop a sensitive liquid biopsy platform. In May 2018, Grail, a U.S.-based biotechnology company, raised $ 1 billion in venture capital and began early breast cancer research with 120,000 patients. In January 2018, researchers at Johns Hopkins University developed a test called CancerSEEK. The analysis includes more than 1,000 patients with nonmetastatic stage I to III ovary, stomach, liver, pancreas, esophagus, lung, colorectal, and breast cancer. Large-scale liquid biopsy studies aimed at facilitating early cancer diagnosis may lead the market over the forecast period.

With the advantages of liquid biopsy over solid tissue biopsy, the European Liquid Biopsy Market is presumed to show modest growth over the forecast period. In addition, the growing number of cancer patients and increasing awareness of minimally invasive cancer patients are supposed to drive market growth. Furthermore, the increase in pre-screening programs for cancer detection is presumed to provide market expansion opportunities.

The European liquid biopsy market is growing due to the high incidence of cancer and rising medical costs. Therefore, the region is foreseen to multiply concerning the development and use of liquid biopsy techniques.

The market players' increasing investment for growth and adoption of new technologies by hospital providers is expected to drive market growth in the region.

However, alternatives to liquid biopsy, uncertain reimbursement, and regulatory conditions are anticipated to hamper the regional market growth. High testing costs, a shortage of trained professionals, and fewer reimbursement policies can limit the growth of the European liquid biopsy market.

This research report on the European Liquid Biopsy Market has been segmented and sub-segmented market into the following categories:

By Cancer Type: 

  • Lung Cancer
  • Pancreatic Cancer
  • Leukemia
  • Other Visceral Cancers

By Diagnostic Approach: 

  • Circulating Tumour cells (CTC)
  • Circulating Tumour DNA (ctDNA)
  • RNA in exosomes
  • Extra-Cellular Vesicles

By End-Users: 

  • Reference Laboratories
  • Hospital/Physician Laboratories
  • Academic and Research Centers
  • Other End Users

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Regionally, the Europe region is also showing high growth in liquid biopsy in the future. An increase in population, patients who have cancer, increasing awareness within the people, and the need to detect and recover cancer drive the market. Lung cancer is one of the most common diseases in European countries.

The number of cancer patients in the UK is increasing, where around 367,000 new cases are found every year. Most of the patient who dies is because of late detection, and liquid biopsy is used to detect and treat various types of cancer such as lung, breast, prostate, and bowel. The government and non-government organizations are promoting a liquid biopsy, which is likely to bolster the market's demand. Growing expenditure on healthcare, especially in urban areas, is promoting the growth rate of the market. Many clinical trials are going on in the UK to develop an innovative treatment procedure for cancer.

Germany has the highest market in the European region, following the UK. There is a substantial rise in the number of cancer patients in Germany. The government in Germany is collaborating with biotech companies to improve liquid biopsy techniques. Many institutes in Germany are researching liquid biopsy.

In France, the market share is to have a significant growth rate in the coming years. Government funding and growing prevalence to improve healthcare services are fueling the demand of the market. In addition, there is a liquid biopsy online platform called Biobank Cote d’Azur. The launch of new products is also one of the factors for the market to grow.

Over 50% of total death in Spain is caused due to cancer. Thus, liquid biopsy is used on a large scale to detect cancer at an early stage. There is a lab for the treatment of cancer in Spain. The liquid biopsy market is growing at a good rate in Italy.

KEY MARKET PLAYERS:

A few of the noteworthy companies operating in the Europe Liquid Biopsy Market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Cancer Type                                         

                                5.1.1 Lung Cancer                           

                                5.1.2 Pancreatic Cancer                

                                5.1.3 Leukemia                

                                5.1.4 Other Visceral Cancers                       

                5.2 By Sample Type                                        

                                5.2.1 Blood                        

                                5.2.2 Urine                         

                                5.2.3 Plasma                      

                                5.2.4 Saliva                         

                                5.2.5 Cerebrospinal                        

                5.3 By Diagnostic Approach                                        

                                5.3.1 Circulating Tumour cells (CTC)                        

                                5.3.2 Circulating Tumour DNA (ctDNA)                  

                                5.3.3 RNA in exosomes                 

                                5.3.4 Extra-Cellular Vesicles                        

                5.4 By End Users                                             

                                5.4.1 Reference Laboratories                     

                                5.4.2 Hospital/Physician Laboratories                     

                                5.4.3 Academic and Research Centers                    

                                5.4.4 Other End Users                   

6. Geographical Analysis                                                              

                                6.1 Introduction                              

                                6.2 U.K                

                                6.3 Spain                             

                                6.4 Germany                     

                                6.5 Italy                               

                                6.6 France                          

7. Strategic Analysis                                                       

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                      

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services               

                                7.2.5 Competitive Rivalry within the Industry                      

8. Market Leaders' Analysis                                                        

                8.1 Janssen Diagnostics                                

                                8.1.1 Overview                

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                            

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Qiagen                                         

                8.3 Rarecells SAS                                             

                8.4 Silicon Biosystems                                   

                8.5 SRI International                                      

                8.6 Myriad Genetics                                      

                8.7 Natera                                          

                8.8 Personal Genome Diagnostics                                            

                8.9 Sysmex Inostics                                        

                8.10 Trovagene                                

                8.11 Exosome Diagnostics                                           

                8.12 HansaBiomed OU                                  

9. Competitive Landscape                                                           

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                        

                9.3 Agreements, collaborations and Joint Ventures                                          

                9.4 New Product Launches                                          

10. Expert Opinions                                                        

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Liquid Biopsy Market, By Region, From 2021 to 2026 (USD Billion)
  2. Europe Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  3. Europe Lung Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  4. Europe Pancreatic Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  5. Europe Leukemia Market, By Region, From 2021 to 2026 (USD Billion)
  6. Europe Other Visceral Cancers Market, By Region, From 2021 to 2026 (USD Billion)
  7. Europe Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  8. Europe Blood Market, By Region, From 2021 to 2026 (USD Billion)
  9. Europe Urine Market, By Region, From 2021 to 2026 (USD Billion)
  10. Europe Plasma Market, By Region, From 2021 to 2026 (USD Billion)
  11. Europe Saliva Market, By Region, From 2021 to 2026 (USD Billion)
  12. Europe Cerebrospinal Market, By Region, From 2021 to 2026 (USD Billion)
  13. Europe Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  14. Europe Circulating Tumour cells (CTC) Market, By Region, From 2021 to 2026 (USD Billion)
  15. Europe Circulating Tumour DNA (ctDNA) Market, By Region, From 2021 to 2026 (USD Billion)
  16. Europe RNA in exosomes Market, By Region, From 2021 to 2026 (USD Billion)
  17. Europe Extra-Cellular Vesicles Market, By Region, From 2021 to 2026 (USD Billion)
  18. Europe Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)
  19. Europe Reference Laboratories Market, By Region, From 2021 to 2026 (USD Billion)
  20. Europe Hospital/Physician Laboratories Market, By Region, From 2021 to 2026 (USD Billion)
  21. Europe Academic and Research Centers Market, By Region, From 2021 to 2026 (USD Billion)
  22. Europe Other End Users Market, By Region, From 2021 to 2026 (USD Billion)
  23. U.K Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  24. U.K Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  25. U.K Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  26. U.K Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)
  27. Spain Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  28. Spain Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  29. Spain Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  30. Spain Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)
  31. Germany Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  32. Germany Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  33. Germany Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  34. Germany Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)
  35. Italy Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  36. Italy Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  37. Italy Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  38. Italy Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)
  39. France Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  40. France Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  41. France Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  42. France Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample